Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma

About the trial

Sponsor

Genmab (with AbbVie)

Tested

Epcoritamab (drug), Rituximab (drug), Lenalidomide (drug)

Dates

Started 2022-09-20; completion 2029-12

Results posted

Not yet

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one o…

From ClinicalTrials.gov, last updated 2026-07-08. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $1.4M in research payments for this study in 2025 (242 payments).

Products named: Epkinly

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.